CD274 and cervical carcinoma: Recent studies showed pembrolizumab with lenvatinib is effective in MSI-H (microsatellite instability-high) advanced EC and conditionally approved for PD-L1-positive cervical cancer, with additive effects in MSS (microsatellite-stable) tumors, suggesting improved survival rates.